We are pleased to report that our raise goal has been reached. We expect to close our $2 M seed round substantially oversubscribed in October, 2019.
Key Members on Our Team:
CEO & Co-Founder
Mr. Northrup brings broad experience to Stingray, having worked at Eli Lilly and Company as a senior executive Corporate Business Development and Strategy, where he did over 40 deals on the buy side for Lilly, as well as in Finance, Marketing, and Sales; in management consulting with Asian companies, and in founding the venturing group with Jubilant Life Sciences.
Mr. Northrup is a Certified Licensing Professional in the Licensing Executive Society, received his MBA from the Wharton School of the University of Pennsylvania in Finance, and received his BA in Economics from Northwestern University.
Sunil Sharma, MD FACP
Chief Medical Officer, Co-Founder, Inventor
Dr. Sharma is Deputy Director, Clinical Sciences; Professor and Division Director, Applied Cancer Research and Drug Discovery, Translational Genomics Research Institute (TGen); Chief, Translational Oncology Research & Drug Discovery; HonorHealth Research Institute. Previously he was the Jon and Karen Huntsman Presidential Professor for Cancer Research, Deputy Center Director, at the Huntsman Cancer Institute at the University of Utah. Dr. Sharma has conducted over 150 phase 1-2 oncology clinical trials as primary investigator over the past 15 years. Dr. Sharma was a VP at Novartis in charge of their early clinical oncology program, started the G/I oncology investigational program at the Nevada Cancer Institute in Las Vegas. Dr. Sharma has also worked at Sloan Kettering Memorial Hospital, one of the most prestigious cancer hospitals in the world.
Mohan Kaadige, PhD
Head of Biology
Dr. Kaadige is a research scientist with a deep passion for understanding the mechanisms and signaling pathways involved in the development and progression of cancer. At TGen, Dr. Kaadige works closely with Dr. Sharma and Dr. Vankayalapati to develop targeted cancer therapy programs. The team uses a combination of computational drug design, synthetic chemistry and biology to discover small molecule inhibitors for cancer therapy. Dr. Kaadige applies his skills to investigate proof of mechanism for novel inhibitors.
Hari Vankayalapati, PhD, Pharm D
Dr. Vankayalapati is an experienced research medicinal chemist and in-silico small molecule designer. He is currently a Professor at the Huntsman Cancer Institute and has had an amazing career between biotech and academic appointments, with more than 20 molecules which have gone into clinical development that he has designed. He has worked in Supergen, Montigen, and has other biotechs he is involved with.
Monil Shah, Pharm D, MBA
VP of Development
Monil is a 20 year experienced pre-clinical and clinical drug developer, having worked at a number of biotech and pharmaceutical companies in this capacity, including WindMIL Therapeutics, IRX Therapeutics /Brooklyn ImmunoTherapeutics, Bristol Myers Squibb, Ventrus Biosciences, Assembly Biosciences, Celgene Corporation, Fibrogen, Novacea, Novartis, and Amgen. Dr. Shah received his BS and PharmD degrees from Rutgers University in New Jersey and his MBA from Florida Institute of Technology.
Business & Operation
Chief Financial Advisor
Mr. Jordan is an accomplished life sciences professional with more than 25 years of investment banking and corporate experience in negotiating strategic corporate alliances, securing international licensing agreements, building national sales teams, and contributing to successful product development, approval and launch. Prior to joining Stingray, Scott was an investment banker with Healthios Capital Markets and employed in business development and commercialization roles with NeoPharm, Akorn Ophthalmics, and Abbot Laboratories
Mr. Jordan earned a BA from Michigan State University, Masters of Business Administration from Kellstadt Graduate School of Management (DePaul).
Uma Bhatt, CPA
Chief Accounting Officer
Ms. Bhatt is a professional CPA with extensive hands on and executive management experience as a CFO, COO, Corporate Controller, SEC Reporting with international experience of Controllership, Business Development Executive, Internal Audit, Tax, Sarbanes-Oxley, SEC Reporting, Project Manager and Risk Management.
Dan Von Hoff, MD, FACP
Michael Berens, PhD
Brain Tumor Advisor
JP Morgan Chase
Wilson, Sonsini, et. al
Get in touch and we’ll get back to you as soon as we can. Thanks.